Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Site for Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma

Determine the maximum tolerated dose or maximum administered dose of MEDI5752 combined with axitinib Assess the safety and tolerability of MEDI5752 combined with axitinib Assess the antitumor activity of MEDI5752 combined with axitinib
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04522323
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Body weight > 35 kg
Histologically or cytologically proven advanced RCC
Advanced RCC not previously treated in that setting
Must have at least 1 measurable lesion according to RECIST v1.1
Life expectancy ≥ 12 weeks
Exclusion Criteria:
Previous treatment with axitinib
Previous treatment with mTOR inhibitors, PD-1, PD-L1, or CTLA-4 inhibitors for RCC
History of active primary immunodeficiency
History of organ transplant
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA